Takeda Enters Partnership to Develop Psychiatric Treatments
Takeda Pharmaceutical, a New England Council member, has partnered with Neurocrine Biosciences to develop and commercialize several treatments currently in Takeda’s research pipeline to treat psychiatric conditions.
The two life sciences companies will collaborate on research focused on developing treatments for psychiatric disorders including schizophrenia, depression, and anhedonia. Both companies are committed to the research and creation of effective treatments for under-addressed neurological disorders. Takeda will assist Neurocrine Biosciences with funding of the research and commercialization of the therapies developed. Neurocrine Biosciences is currently working on three therapies that are ready to begin Phase II studies.
“With longstanding experience developing and commercializing therapies for serious neurological and psychiatric disorders, Neurocrine Biosciences is the ideal partner to continue to develop our early-to-mid-stage psychiatry portfolio and bring these potential new therapies to patients,” said Sarah Sheikh, Head of the Neuroscience Therapeutic Area Unit at Takeda.
The Council congratulates Takeda on this important research partnership to serve the unmet needs of patients with challenging neurological disorders. Business Wire reports.
Recently from the Blog
June 30 Bi-Weekly Round-Up: NEC Members Contribute to COVID-19 Crisis Response